RESUMO
Despite the devastating toll of the overdose crisis in the United States, many addiction treatment programs do not offer medications for opioid use disorder (MOUD). Several states have incorporated MOUD requirements into their standards for treatment program licensure. This study examined policy officials' and treatment providers' perspectives on the implementation of these policies. During 2020-22, we conducted thirty-one semistructured interviews with forty policy officials and treatment providers in nine states identified through a legal analysis. Of these states, three states required treatment organizations to offer MOUD, and two prohibited organizations from denying admission to people receiving MOUD. Qualitative findings revealed that licensure policies were part of a broader effort to transition the specialty treatment system to a model of care more consistent with medical evidence; states perceived tension between raising quality standards and maintaining adequate treatment capacity; aligning other state policies with MOUD access goals facilitated implementation of the licensure requirement; and measuring compliance was challenging. Licensure may offer states an opportunity to take a more active role in ensuring access to effective treatment.
Assuntos
Acessibilidade aos Serviços de Saúde , Licenciamento , Transtornos Relacionados ao Uso de Opioides , Humanos , Estados Unidos , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Tratamento de Substituição de Opiáceos , Política de Saúde , Entrevistas como Assunto , Governo Estadual , Pesquisa QualitativaRESUMO
Physicians are trending towards practice consolidation nationally; however, changes in dermatology practice size remain to be assessed. The objective of this study was to analyze trends in dermatology practice size from 2012 to 2020 using a large-scale Medicare physician database. We performed a retrospective cross-sectional analysis using 2012 and 2020 data obtained from the Physician Compare Database. Responses from dermatologists were analyzed for trends in practice size, with a sub-analysis to examine differences among different regions, gender, and years of experience. The proportion of dermatologists in solo practice decreased from 26.1% in 2012 to 15.6% in 2020 (p < 0.001). Dermatologists were 40% less likely to be practicing in solo practice and 36% more likely to be in a practice with 10 or more members in 2020 (p < 0.001). These findings were consistent among all regions and genders examined. Additionally, in 2020, dermatologists with 30 or more years in practice were 7.5 times more likely to be in solo practice compared to dermatologists with 0-9 years in practice (p < 0.001). There is a trend of dermatologists working for larger practices, which is consistent with a larger nationwide trend of expanding physician practices. This shift in practice settings should be closely monitored to analyze the effect on healthcare efficiency, cost, and delivery.
Assuntos
Dermatologia , Médicos , Idoso , Humanos , Masculino , Feminino , Estados Unidos , Estudos Transversais , Medicare , Estudos RetrospectivosRESUMO
OBJECTIVE: To develop and implement a measure of how US hospitals contribute to community health with a focus on equity. DATA SOURCES: Primary data from public comments and hospital surveys and secondary data from the IBM Watson Top 100 Hospitals program collected in the United States in 2020 and 2021. STUDY DESIGN: A thematic analysis of public comments on the proposed measure was conducted using an iterative grounded approach for theme identification. A cross-sectional survey of 207 hospitals was conducted to assess self-attestation to 28 community health best practice standards in the revised measure. An analysis of hospital rankings before and after inclusion of the new measure was performed. DATA COLLECTION/EXTRACTION METHODS: Public comment on the proposed measure was collected via an online survey, email, and virtual meetings in 2020. The survey of hospitals was conducted online by IBM in 2021. The analysis of hospital ranking compared the 2020 and 2021 IBM Watson Top 100 Hospitals program results. PRINCIPAL FINDINGS: More than 650 discrete comments from 83 stakeholders were received and analyzed during measure development. Key themes identified in thematic analysis included equity, fairness, and community priorities. Hospitals that responded to a cross-sectional survey reported meeting on average 76% of applicable best practice standards. Least met standards included providing emergent buprenorphine treatment for opioid use disorder (53%), supporting an evidence-based home visiting program (53%), and establishing a returning citizens employment program (27%). Thirty-seven hospitals shifted position in the 100 Top Hospital rankings after the inclusion of the new measure. CONCLUSIONS: There is broad interest in measuring hospital contributions to community health with a focus on equity. Many highly ranked hospitals report meeting best practice standards, but significant gaps remain. Improving measurement to incentivize greater hospital contributions to community health and equity is an important priority.
Assuntos
Hospitais , Saúde Pública , Estados Unidos , Humanos , Saúde Pública/métodos , Estudos Transversais , Inquéritos e QuestionáriosRESUMO
The complexity and inefficiency of the U.S. health care system complicates the distribution of life-saving medical technologies. When the public health is at stake, however, there are alternatives. The proposal for a national PrEP program published in this issue of the Journal applies some of the lessons of the national COVID vaccine campaign to HIV prevention. In doing so, it draws on other examples of public health approaches to the financing of medical technology, from vaccines for children to hepatitis C treatment.
Assuntos
COVID-19 , Infecções por HIV , Vacinas , COVID-19/prevenção & controle , Vacinas contra COVID-19 , Criança , Infecções por HIV/prevenção & controle , Humanos , Preparações FarmacêuticasRESUMO
This special edition of JLME centers on a novel proposal for a national PrEP access program with the potential to break through a failed status quo.
Assuntos
Infecções por HIV , Profilaxia Pré-Exposição , Infecções por HIV/prevenção & controle , HumanosRESUMO
The U.S. has the tools to end the HIV epidemic, but progress has stagnated. A major gap in U.S. efforts to address HIV is the under-utilization of medications that can virtually eliminate acquisition of the virus, known as pre-exposure prophylaxis (PrEP). This document proposes a financing and delivery system to unlock broad access to PrEP for those most vulnerable to HIV acquisition and bring an end to the HIV epidemic.
Assuntos
Epidemias , Infecções por HIV , Profilaxia Pré-Exposição , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , HumanosAssuntos
Dicetopiperazinas/uso terapêutico , Infecções por HIV/prevenção & controle , Inibidores de Integrase de HIV/uso terapêutico , Piridonas/uso terapêutico , Custos e Análise de Custo , Dicetopiperazinas/economia , Inibidores de Integrase de HIV/economia , Equidade em Saúde , Acessibilidade aos Serviços de Saúde , Humanos , Piridonas/economiaAssuntos
Administração em Saúde Pública , Prática de Saúde Pública , United States Public Health Service/organização & administração , Acreditação , Governo Federal , Política de Saúde , Mão de Obra em Saúde/estatística & dados numéricos , Governo Local , Administração em Saúde Pública/normas , Governo Estadual , Estados UnidosAssuntos
Betacoronavirus , Infecções por Coronavirus/economia , Infecções por Coronavirus/epidemiologia , Renda , Seguradoras/economia , Seguro Saúde/economia , Pandemias/economia , Pneumonia Viral/economia , Pneumonia Viral/epidemiologia , COVID-19 , Recessão Econômica , Gastos em Saúde/legislação & jurisprudência , Humanos , Alocação de Recursos/economia , Alocação de Recursos/métodos , SARS-CoV-2 , Estados Unidos/epidemiologiaRESUMO
The National Institutes of Health is investing hundreds of millions of dollars into new research on opioids. As these studies yield insights and results, their results will have to change policy and practice before they can bend the curve of the epidemic. However, the United States does not have a strong track record of translating evidence on drug policy into action. Three reasons for the translation gap are the historical legacy of drugs in the United States, vested interests, and politics. Researchers can become engaged in policy and political processes to strengthen the US response.